Convalescent plasma from cured coronavirus disease (COVID) patients as a therapy for patients with severe COVID disease (CONCOVID)
- Conditions
- CoronavirusCOVID-19SARS-CoV-210047438
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 87
Patients
• Patients with PCR confirmed COVID disease
• The most recent PCR positive sample is <96hrs old
• Patient admitted to the hospital <7 days
• Age >=18
• Written informed consent by patient or legal patient representative
Donors:
• Tested negative for HIV, HBV, HCV, HEV, HTLV and syfilis
• A history of COVID infection that was documented by PCR
• Known ABO-Resus(D) blood group
• A screening for irregular antibodies with a titer <= 1:32
• Asymptomatic for at least 14 days
• Written informed consent regarding the plasmapheresis procedure
Patients
• Participation in another intervention trial on the treatment of COVID-19 that
falls under the
Dutch law human research (WMO)
• Already on mechanical ventilation for >96hrs
• IgA deficiency
Donors:
• Age <18 years or age >65 years
• Weight <50 kg
• Medical history of heart failure
• History of transfusion with red blood cells, platelets or plasma after
01-01-1980
• History of organ- or tissue transplant
• A cumulative stay in the United Kingdom of >= 6 months in the period between
01-01-1980 and
31-12-1996
• A history of i.v. drug use
• Insulin dependant diabetes
• An underlying severe chronic illness (i.e. history of heart failure, cancer
or stroke)
• Tested positive for HLA- or HNA-antibodies
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method <p>• Overall mortality until discharge from the hospital or a maximum of 60 days<br /><br>after admission whichever comes first</p><br>
- Secondary Outcome Measures
Name Time Method